BeiGene
BGNE
#982
Rank
NZ$35.52 B
Marketcap
$324.70
Share price
0.49%
Change (1 day)
28.96%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$27.43

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$29.25. In 2022 the company made an earnings per share (EPS) of -$34.05 a decrease over its 2021 EPS that were of -$26.74.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$27.43-19.44%
2022-$34.0527.35%
2021-$26.74-19.96%
2020-$33.4120.81%
2019-$27.6531.52%
2018-$21.02417.57%
2017-$4.06-37.16%
2016-$6.46158.95%
2015-$2.50

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.76-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.47-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA